Stimulant use disorder: amphetamine-type stimulants. Estimated 12-month prevalence
of amphetamine-type stimulant use disorder in the United States is 0.2% among 12- to 17-
year-olds and 0.2% among individuals 18 year s and older. Rates are similar among adult
males and females (0.2%), but among 12- to 17- year-olds, the rate for females (0.3%) is
greater than that for males (0.1%). Intravenou s stimulant use has a male-to-female ratio of
3:1 or 4:1, but rates are more balanced amon g non-injecting users, with males representing
54% of primary treatment admissions. Twelve -month prevalence is greater among 18- to
29-year-olds (0.4%) compared with 45- to 64-ye ar-olds (0.1%). For 12- to 17-year-olds, rates
are highest among whites and African Americans (0.3%) compared with Hispanics (0.1%)
and Asian Americans and Pacific Islanders (0.01%), with amphetamine-type stimulant use
disorder virtually absent among Native Americans. Among adults, rates are highest among
Native Americans and Alaska Natives (0.6%) compared with whites (0.2%) and Hispanics
(0.2%), with amphetamine-type stimulant use disorder virtually absent among African
Americans and Asian Americans and Pacific Islanders. Past-year nonprescribed use of
prescription stimulants occu rred among 5%–9% of children  through high school, with
5%–35% of college-age persons reporting past-year use.
Stimulant use disorder: cocaine. Estimated 12-month prevalence of cocaine use disorder